Genovis AB initiates sales of GlyCLICK™
Today Genovis is launching GlyCLICK™, a product for specific labeling of antibodies for purposes such as development of biopharmaceuticals.GlyCLICK™ is the first of a series of products based on a technology platform in which Genovis’ unique enzyme GlycINATOR is combined with SiteClick™ technology from Life Technologies. GlyCLICK is a new technology in an expanding market for applications in antibody development, preclinical imaging and antibody drug conjugates (ADCs). The market for biopharmaceuticals is large and many pharmaceutical companies are looking for new and improved technologies